Clinical Trials for Cancer Type: Lung

12 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-12 Optimization of Magnetic Resonance Imaging Applications on the 1.5 and 3.0 Tesla for Cardiovascular and Pulmonary Systems Open
UCI-17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors Open
UCI-17-61 [EXEMPT - RETROSPECTIVE CHART REVIEW] Retrospective survival analysis among patients with non-small cell lung cancer harboring MET exon 14 mutations Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-17-90 A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy Open